Wednesday, 18 Sep 2019

You are here

RheumNow Podcast – Richer or Poorer (5.17.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

  1. Public health study from Norway compares the top 1% richest and bottom 1% poorest found significant difference in life expectancy -14 years for men and 8 years for women. Similar USA study finds roughly the same as in Norway. https://t.co/h1QFZmgXaJ 
  2. Large study from OTIS on PsA and AS shows an increased risk for adverse pregnancy outcomes - including preterm delivery (RR 1.81, 3.82) & Cesarean delivery (RR 1.63, 5.82). Active disease & steroid use may also increase these risks. https://buff.ly/30lTKqI 
  3. Literature review - 23 studies on Natural dietary supplement (NDS) use finds that worldwide 47% of RA pts use NDS, did not differ by geographic region, 47% found NDS to be effective, 13% had adverse side effects, & 30% informed their physicians. https://t.co/N2O16NxuxU 
  4. Reactivation of latent CMV infection is rare in Rheum Pts. 14 pts described w/ febrile illness, on steroids (13), with coinfections (8), 4 died during hospitalization, tend to have longer hospitalizations (47 vs. 7 days), more coinfections (67% vs. 17%) https://t.co/pijtFv55Uq   
  5. Overall prevalence of low back pain among US workers is 26.4%, with 5.6% having severe LBP, according to May 14th Annals of Internal Medicine. https://t.co/5sfYFQWHyh   
  6. PCSK9 inhibitors (ie, Repatha) can safetly be used in Statin-induced HMGCR+ myopathy pts . 8 pts given PCSK9 inhib for hyperlipidemia, showed no Sx worsening, CK levels dropped (956±1137 IU/L to 419±393 IU/L) & HMGCR Ab titers decreased; 2/8 improved https://t.co/iSuPz6ptBY 
  7. Studies argue about MTX efficacy in GCA; many calling for new RCTs at higher doses. A new real world study compared 83 GCA pts on MTX (13.5mg/wk) vs 83 controls showing signif. lower relapse rates with MTX (0.32; 0.24–0.41), but no change in steroid use https://t.co/aCrL4PILUM
  8. DECT is most accurate in diagnosing established gout - review of 10 studies shows a pooled (95% CI) sensitivity of 0.81 (0.77, 0.86) and specificity of 0.91 (0.85, 0.95), respectively. W/ short disease duration (⩽6 wks), sensitivity 0.55 and spec 0.89  https://buff.ly/2Ecw1Qg 
  9. Medicare analysis shows Gout patients are twice as likely to have chronic pain (HR 2.02; 95% CI 1.98-2.05) and use of allopurinol or febuxostat was associated with a lower risk of chronic pain (HR 0.72-0.79) https://t.co/xW5rVPyC69 
  10. Coexistent Gout Increases Risk in Rheumatoid Arthritis  
  11. Methotrexate Use Not Linked to Interstitial Lung Disease in RA  
  12. Generic Price Fixing Alleged by State Prosecutors   

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – The End of Arthritis (9.13.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Dr. Jack Cush reviews the news and important research published in the last two weeks on RheumNow.com.

Influenza Vaccination Update

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season.

RheumNow Podcast - I Wanna New Drug (8-30-19)

Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.